Antiplatelets Fail to Reduce Life Support Requirement in Critically Ill COVID-19 Patients

These drugs may, however, modestly improve overall survival at three months.

Related Keywords

Bristol ,City Of ,United Kingdom ,Boston ,Massachusetts ,United States ,London ,Anthony Gordon ,Paul Ridker ,Jean Connors ,Charlotte Bradbury ,University Of Bristol Medical School ,Imperial College London ,Medical School ,Professor Anthony Gordon ,Covid 19 ,019 Novel Coronavirus ,019 Ncov ,Uhan Coronavirus ,Uman Coronavirus Hku1 ,Uman Coronavirus Oc43 ,Cov Oc43 ,Uman Coronavirus 229e ,Cov 229e ,Corona Virus ,Ovid19 ,Ovel Coronavirus Sars Cov 2 ,Critical Illness ,Uk Site Content United Kingdom ,Uk ,Antiplatelet Agent ,Aspirin ,Acetylsalicylic Acid ,Hospitals ,Anti Inflammatory Agents ,